Woundsome Revascularization in Chronic Limb-Threatening Ischemia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssiut University

About this trial

Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease and remains a major health problem. Although the angiosome concept was introduced to guide revascularization by restoring direct blood flow to the affected tissue, its usefulness is limited by anatomical variations, collateral circulation, and wounds involving multiple territories. The emerging "woundsome" concept focuses instead on improving arterial perfusion directly to the wound area, recognizing that both direct revascularization and

Eligibility criteria

Qualifiers

None

Disqualifiers

Patients with unsalvageable limbs

Patients with acute limb ischemia (ALI)

Patients with contraindications to contrast medium

Patients with aortoiliac or femoropopliteal occlusive disease

Trial design

Treatments tested in this trial

  • Revascularization by Percutaneous Transluminal Angioplasty

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators